Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca gives Actavis generic Crestor head start

This article was originally published in Scrip

Executive Summary

AstraZeneca has granted Actavis a head start in the race to cash in on the loss of US market exclusivity of Crestor (rosuvastatin calcium), its top-selling drug, in 2016. The latter had been attempting to bypass the usual process of generic market entry by threatening to launch a similar, but not substitutable, version of rosuvastatin, forcing AstraZeneca to argue patent infringement in the courts to defend its top-selling product.

Advertisement
Advertisement

Related Content

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020841

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel